PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Early Dobutamine Response, Not Echo, Flags Better Sepsis Trajectory

dobutamineinotropesseptic shocksepsis-induced myocardial dysfunctionnorepinephrine-equivalentScvO2echocardiographyvasopressorsretrospective cohorthemodynamicscritical care Critical Care / ICU

Background Information

Dobutamine response in septic shock predicts better outcomes.

Dobutamine is used in septic shock with myocardial dysfunction, but predictors of response are unclear. Responders to dobutamine showed lower 28-day ICU mortality (41% vs. 58%; p = 0.13) and more ICU-free days (17 vs. 0; p = 0.017). Early responsiveness to dobutamine identifies patients with better outcomes, but baseline echocardiography did not predict response. Dobutamine responders in septic shock have better clinical outcomes.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Tarbaghia M, Nanah A, Sato R, Sanfilippo F, Dugar S

Citation: Tarbaghia M, Nanah A, Sato R, et al. Response to Dobutamine in Septic Shock With Myocardial Dysfunction: A Single-Center Retrospective Study. Critical care explorations. 2026;8(10):e1487. doi:10.1097/CCE.0000000000001487

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.